The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Open accessAbstract
BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). METHODS: . RESULTS: for superiority). The median duration of follow-up was 15.3 months. After 18 months, the progression-free survival rate was 63.0% (95% confidence interval [CI], 54.6 to 70.3) in the ribociclib group and 42.2% (95% CI, 34.8 to 49.5) in the placebo group. In patients with measurable disease at baseline, the overall response rate was 52.7% and 37.1%, respectively (P<0.001). Common grade 3 or 4 adverse events that were reported in more than 10% of the patients in either group were neutropenia (59.3% in the ribociclib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuation because of adverse events were 7.5% and 2.1%, respectively. CONCLUSIONS: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT01958021 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of exposure to trial treatment in the ribociclib group was 20.2 months (interquartile range, 7.4 to 45.1), which is 7 months longer than it was at the time of the primary analysis of progression-free survival. 10”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the primary and updated analyses of MONALEESA-2, progression-free survival was significantly longer with ribociclib plus letrozole than with placebo plus letrozole (median in updated analysis, 25.3 months vs. 16.0 months; hazard ratio for disease progression or death, 0.57; 95% confidence interval [CI], 0.46 to 0.70; P<0.001).”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data for overall survival were immature at the time of the primary and updated analyses.”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the primary and updated analyses of MONALEESA-2, progression-free survival was significantly longer with ribociclib plus letrozole than with placebo plus letrozole (median in updated analysis, 25.3 months vs. 16.0 months; hazard ratio for disease progression or death, 0.57; 95% confidence interval [CI], 0.46 to 0.70; P<0.001).”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of CDK4/6 inhibitors (ribociclib, abemaciclib, and palbociclib) improved progression-free survival in this patient population, leading to regulatory approvals. 9-13”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
In the citing paper
“However, 10% of the patients treated with abemaciclib develop grade 3 diarrhea, which is very rare with the other two inhibitors (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationMECHANISMS OF ENDOCRINE RESISTANCE IN BREAST CANCER
Osborne, C., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,205
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020299707510 · Cited by 589
Flagged first, then by citations
Research works printed but not linked: 2
- Infante JR, Clin Cancer Res
- Vuppalanchi R, Hepatology
Cited by
Sorted by citations
Items 701–800 of 1,000
Pharmacological cancer treatment and venous thromboembolism risk
Martín, A. J. M., Ramírez, S. P., Morán, L. O., Zamorano, M. R., Viñuela-Benéitez, M. C., Aparicio, I., Escobar, I. G., & Soria, J. M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa004 · Cited by 21
What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care
Anders, C. K., LeBoeuf, N. R., Bashoura, L., Faiz, S. A., Shariff, A. I., & Thomas, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279465 · Cited by 21
Fuentes‐Antrás, J., de Luna, A., de Sá, A. L., Ocaña, A., García-Sáenz, J. Á., & Moreno, F. (2020) · The Breast · doi:10.1016/j.breast.2020.10.007 · Cited by 22
“In this regard, grade 3 elevation of alanine and aspartate aminotransferases occurred in up to 11% and 6% of patients receiving ribociclib or abemaciclib in RCTs [2,4,8].”
BackgroundInfluentialCottu, P. H., Ring, A. E., Abdel‐Razeq, H., Marchetti, P., Cardoso, F., Bofill, J. S., Martín, M., Menon-Singh, L., Wu, J., & Laurentiis, M. D. (2022) · The Breast · doi:10.1016/j.breast.2022.01.016 · Cited by 22
“In terms of therapeutic outlook, while the overall patient population included in the CompLEEment-1 trial has similarities with the MONALEESA-2 and -7 trials [22,25], the more permissive inclusion criteria of CompLEEment-1 means that these results should prove useful to clinicians in the real-world setting.”
ResultAdvanced Cancer as a Chronic Disease: Introduction
Pituskin, E., Joy, A. A., & Fairchild, A. M. (2021) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2021.151176 · Cited by 22
Garrido-Castro, A. C., Graham, N., Ali, L. R., Herold, C. I., Desrosiers, J., Do, K., Parsons, H. A., Li, T., Goel, S., DiLullo, M. K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010430 · Cited by 20
DCAF16-Based Covalent Degradative Handles for the Modular Design of Degraders
Orr, L. M., Tomlinson, S. J., Grupe, H. R., Lim, M., Ho, E., Yilmaz, H., Zhou, G., Leon, B., Olzmann, J. A., & Nomura, D. K. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00959 · Cited by 22
“…we next generated compounds linking this handle onto several different types of protein-targeting ligands, including the CDK4/6 inhibitor ribociclib 35 , the SMARCA2/4 bromodomain inhibitor SGC SMARCA-BRDVIII 36,37 , and an androgen receptor (AR) antagonist from the AR PROTAC ARV-110 38 to…”
Chen, D. H., Tyebally, S. M., Mallouppas, M., Roylance, R. R., Spurrell, E. L., Raja, F. A., & Ghosh, A. K. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01446-x · Cited by 21
Jurić, V., Hudson, L., Fay, J., Richards, C. E., Jahns, H., Verreault, M., Bielle, F., Idbaïh, A., Lamfers, M. L. M., Hopkins, A. M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04050-7 · Cited by 19
Olazagasti, C., Lee, C., Liu, A., Stefanov, D. G., & Cheng, K. C. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211050106 · Cited by 21
Gión, M., Pérez-García, J. M., Llombart‐Cussac, A., Sampayo-Cordero, M., Cortés, J., & Malfettone, A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059587 · Cited by 20
Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
Torregrosa, M. D., Barco, S. D., Cotes, A., Roso, L. L., Servitja, S., & Sarrió, R. G. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02766-8 · Cited by 22
“MONALEESA-2 is a phase III trial comparing the combination of ribociclib and letrozole with letrozole monotherapy as the first line of treatment [33, 43].”
BackgroundSartaj, A., Annu, Alam, M., Biswas, L., Yar, M. S., Mir, S. R., Verma, A. K., Baboota, S., & Ali, J. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2104292 · Cited by 20
“The reason might be explained by the fact that RBO acts on overexpressed CDK4/6 receptor (site-specific) which is present in tumour cells and antagonising CDK4/6 activity, affecting the further cell division which could be a possible major setback and does not cause histopathological aberrations to the breast tissues…”
BackgroundCDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 22
Douganiotis, G., Kesisis, G., Lalla, E., Korantzis, I., Boukovinas, I., & Papazisis, K. T. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10146 · Cited by 21
Queiroz, M. M., Sacardo, K. P., Ribeiro, M. F., Gadotti, L. L., Saddi, R., Oliveira, L. J. D. C., Linck, R. D. M., Cruz, M. R. D. S., Barroso‐Sousa, R., Sahade, M., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100683 · Cited by 21
Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
Hu, Q., & Huang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108939 · Cited by 23
Martel, S., Bruzzone, M., Ceppi, M., Maurer, C., Ponde, N. F., Ferreira, A. R., Viglietti, G., Mastro, L. D., Prady, C. C. M., de Azambuja, E., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.009 · Cited by 21
Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer
Cabetas, M. G.-T., Martínez, P. L., Jiménez‐Nácher, I., Díaz‐Almirón, M., Zamora, P. M., & Ambrosio, A. H. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01193-z · Cited by 23
Ribociclib for HR-Positive, Advanced Breast Cancer
Gramont, A. D. E., Herrera, A., & de Gramont, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1615255 · Cited by 20
CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment
Meunier, L., Martin, E. D., Delire, B., Jacot, W., Guiu, S., Zahhaf, A., Larrey, D. G., & Horsmans, Y. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101098 · Cited by 22
Huber, M., Bauer, L. S., Gruber, F. K., & Müller, E. W. (2025) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/sjnxeirzxn · Cited by 19
Matikas, A., Foukakis, T., & Bergh, J. C. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.002 · Cited by 19
Lin, C., Lee, L., Wang, T., Hsu, C., Tsai, C.-L., Chao, A., & Lai, C. (2019) · Cancers · doi:10.3390/cancers11071025 · Cited by 19
Saux, O. L., Lardy-Cléaud, A., Frank, S., Debled, M., Cottu, P. H., Pistilli, B., Vanlemmens, L., Leheurteur, M., Lévy, C., Laborde, L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.014 · Cited by 21
Self-citationKawakami, M., Mustachio, L. M., Chen, Y., Chen, Z., Liu, X., Wei, C.-H., Roszik, J., Kittai, A. S., Danilov, A. V., Zhang, X., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0987 · Cited by 19
“Although pharmacologic inhibition of specific CDK family members such as CDK4/6 is FDA approved for a subset of breast cancers (21, 22), clinical validation of CDK2 inhibitors for cancer therapy is not yet established.”
A review of the endocrine resistance in hormone-positive breast cancer.
Chien, T.-J. (2021) · PubMed · Cited by 22
Bolzacchini, E., Pomero, F., Fazio, M., Civitelli, C., Fabro, G., Pellegrino, D., Giordano, M., & Squizzato, A. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.009 · Cited by 21
Ribociclib-Induced Pseudo-Acute Kidney Injury
Sy‐Go, J. P. T., Yarandi, N., Schwartz, G. L., & Herrmann, S. M. (2022) · Journal of Onco-Nephrology · doi:10.1177/23993693221085285 · Cited by 19
“6(1-2) 64 –69 © The Author(s) 2022 Article reuse guidelines: sagepub.”
Pasqualoni, M., Orlandi, A., Palazzo, A., Garufi, G., Cannizzaro, M. C., Pontolillo, L., Pannunzio, S., Cutigni, C., Sollena, P., Federico, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1067264 · Cited by 21
“3 months with the combination therapy in the Phase 3 MONALEESA-2 study (5).”
BackgroundCurigliano, G., Dent, R. A., Llombart‐Cussac, A., Pegram, M. D., Pusztai, L., Turner, N. C., & Viale, G. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00560-z · Cited by 21
Enhanced Dissolution and Diffusion of Ribociclib by Salt Formation with Fluorobenzoic Acid Coformers
Sangwan, S., Swapna, B., & Nangia, A. K. (2024) · Crystal Growth & Design · doi:10.1021/acs.cgd.3c01460 · Cited by 19
Slower CDK4 and faster CDK2 activation in the cell cycle
Zhang, W., Liu, Y., Jang, H., & Nussinov, R. (2024) · Structure · doi:10.1016/j.str.2024.04.012 · Cited by 30
Daldorff, S., Mathiesen, R. R., Yri, O. E., Ødegård, H. P., & Geisler, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.405 · Cited by 19
“In October 2016, Hortobagyi et al (2016) presented an early report covering a phase III clinical trial evaluating the efficacy of another CDK4/6 inhibitor, ribociclib, combined with letrozole vs letrozole given alone as systemic therapy in MBC patients.”
BackgroundTanioka, M., Mott, K. R., Hollern, D. P., Fan, C., Darr, D. B., & Perou, C. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0597-3 · Cited by 19
Hachem, G. E., Gombos, A., & Awada, A. H. (2019) · F1000Research · doi:10.12688/f1000research.17542.1 · Cited by 20
He, M., Li, J., Zuo, W., Ji, L., Jiang, Y., Hu, X., Wang, Z., & Shao, Z.-M. (2019) · Cancer Medicine · doi:10.1002/cam4.2453 · Cited by 19
Scheinberg, T., Kench, J. G., Stockler, M. R., Mahon, K. L., Sebastian, L. T., Stricker, P. D., Joshua, A. M., Woo, H. H., Thanigasalam, R., Ahmadi, N., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033667 · Cited by 18
Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer
Martín, M., García-Sáenz, J. Á., Manso, L., Llombart‐Cussac, A., Cassinello, A., Atienza, M., Ringeisen, F. P., & Ciruelos, E. (2020) · Future Oncology · doi:10.2217/fon-2020-0604 · Cited by 19
Bardia, A., Modi, S., Oliveira, M., Cortés, J., Campone, M., Ma, B., Dirix, L., Weise, A. M., Hewes, B., Diaz-Padilla, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1068 · Cited by 20
Self-citationLøkkegaard, S., Eliáš, D., Alves, C. L., Bennetzen, M. V., Lænkholm, A., Bak, M., Gjerstorff, M. F., Johansen, L. E., Vever, H., Bjerre, C. A., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00210-8 · Cited by 18
Li, Y., Li, L., Du, Q., Li, Y., Yang, H., & Li, Q. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1910705 · Cited by 19
Watanabe, T., Oba, T., Tanimoto, K., Shibata, T., Kamijo, S., & Ito, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252822 · Cited by 19
Current State of Cell Therapies for Breast Cancer
Gautam, N., Elleson, K. M., Ramamoorthi, G., & Czerniecki, B. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000607 · Cited by 19
Ferrando, L., Vingiani, A., Garuti, A., Vernieri, C., Belfiore, A., Agnelli, L., Dagrada, G. P., Ivanoiu, D., Bonizzi, G., Munzone, E., et al. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010563 · Cited by 19
Cytokine-induced senescence for cancer surveillance
Wieder, T., Brenner, E., Braumüller, H., Bischof, O., & Röcken, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9667-z · Cited by 20
Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer
Flaum, L., & Gradishar, W. J. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_9 · Cited by 19
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Klocker, E. V., Egle, D., Bartsch, R., Rinnerthaler, G., & Gnant, M. (2025) · Drugs · doi:10.1007/s40265-024-02144-y · Cited by 21
Ayyagari, R., Tang, D. H., Patterson‐Lomba, O., Zhou, Z., Xie, J., Chandiwana, D., Dalal, A. A., & Niravath, P. A. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.004 · Cited by 18
“Volume 40 Number 4 LEE+AI Pal+AI Ful250+AI Ful500 Hortobagyi (2016) Finn (2016) Finn (2015) Robertson (2016)Mehta (2012) AI Core analysis LEE+AI Pal+AI Hortobagyi (2016) Finn (2016)AI Late progressers analysis LEE+AI Pal+AI Ful500 Hortobagyi (2016) Finn (2016) Finn (2015) Robertson (2016) AI De novo analysis Figure 2.”
BackgroundInfluentialSevere rhabdomyolysis induced by possible drug–drug interaction between Ribociclib and Simvastatin
Streicher, C., Daulange, A., Madranges, N., & Vayre, L. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220945365 · Cited by 19
“Cyclin-dependent kinases inhibitors 4 and 6 (CDK4/6) are indeed widely used, combined with hormonal treatment as first-line therapy.(1) In this indication, three CDK4/6 inhibitors, Palbociclib, Ribociclib and Abemaciclib, have been approved by the FDA and the EMA.”
BackgroundT Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
Klein, K., Witalisz‐Siepracka, A., Gotthardt, D., Agerer, B., Sternberg, F., Grausenburger, R., Knab, V. M., Bergthaler, A., & Sexl, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650977 · Cited by 19
The Effects of HER2 on CDK4/6 Activity in Breast Cancer
Sinclair, W., & Cui, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.08.007 · Cited by 21
Iuliani, M., Simonetti, S., Ribelli, G., Napolitano, A., Longo, U. G., Vincenzi, B., Orsaria, P., Denaro, V., Tonini, G., Santini, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052477 · Cited by 19
Shen, L., Zhou, J., Chen, Y., Ding, J., Wei, H., Liu, J., Xia, W., Xie, B., Xie, X., Li, X., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4767 · Cited by 17
Welslau, M., Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., Schütz, F., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9952 · Cited by 18
“P a l o m a - 2 [ 54 ] P a l o m a - 3 [ 55 , 56 ] M on a l ee s a - 2 [ 57 , 58 ] M on a l ee s a - 3 [ 5 ] M on a l ee s a - 7 [ 59 ] M on a r c h - 2 [ 60 ] M on a r c h - 3 ▪ R i b o c i c li b : 87 .”
Self-citationContemporary breast cancer treatment-associated thrombosis
Kirwan, C., & Blower, E. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.025 · Cited by 18
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 20
Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer
Jimenez, R., Schenkel, C., Levit, L. A., Hu, B., Lei, X. J., Harvey, R. D., Morrison, V. A., Pollastro, T., Waterhouse, D. M., Weekes, C. D., et al. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00427 · Cited by 19
Alsaleh, K. A., Zahwahry, H. A., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel‐Razeq, H., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04588-3 · Cited by 19
“…ET plus a placebo in phase III trials conducted in the upfront setting with large number of subjects (MONALEESA-2 for riboci-clib + letrozole (Hortobagyi et al. 2016); PALOMA-2 (Finn et al. 2016) To assess the radiological responses post-randomization and pre-surgery, we elected to use the…”
West, M. T., Goodyear, S. M., Hobbs, E. A., Kaempf, A. J., Kartika, T., Ribkoff, J., Chun, B., & Mitri, Z. I. (2023) · The Oncologist · doi:10.1093/oncolo/oyad035 · Cited by 18
Tang, H., Yeo, D., DeSouza, K., Ahmad, O., Shafiq, T., Ofor, O., Anand, A., Karim, S., Khan, S. N., & Madhusudan, S. (2023) · Cancers · doi:10.3390/cancers15215164 · Cited by 19
“In conclusion, the real-world data presented here demonstrates that there is no significant difference in median PFS (27.5 months vs. 25.7 months, p = 0.3) or median OS (49.5 months vs. 50.2 months, p = 0.67) in patients who received either palbociclib or ribociclib, respectively.”
BackgroundInfluentialFasching, P. A., Decker, T. W., Hartkopf, A. D., Nusch, A., Heinrich, B., Kurbacher, C. M., Fuchs, R., Tesch, H., Krabisch, P., Huober, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113480 · Cited by 19
Self-citationShao, H., Zhao, M., Guan, A., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · BMC Medicine · doi:10.1186/s12916-023-03238-2 · Cited by 21
CDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 19
“For patients receiving ribociclib, grade 3 or 4 elevations in alanine and aspartate aminotransferase (ALT/AST) were seen between 2–6% higher than those seen in the placebo groups [4, 6, 8].”
InfluentialCyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future
Siskin, M., Economides, M. P., & Wise, D. R. (2025) · Cancers · doi:10.3390/cancers17050774 · Cited by 22
Negasa, D. E., & Sisay, M. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s150540 · Cited by 17
The role of abemaciclib in treatment of advanced breast cancer
McCartney, A., Moretti, E., Sanna, G., Pestrin, M., Risi, E., Malorni, L., Biganzoli, L., & Leo, A. D. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918776925 · Cited by 19
Wan, X., Zhang, Y., Ma, J., Tan, C., Zeng, X., & Peng, L. (2018) · The Breast · doi:10.1016/j.breast.2018.10.004 · Cited by 18
Novel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 18
“Ribociclib was also studied in combination with letrozole and produced similar results (12), with a PFS that was significantly longer than the placebo group (HR 0.”
ResultRecent updates in systemic therapy of breast cancer
Arora, S., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_335_20 · Cited by 18
Ribociclib induced acute kidney injury: A case report
Gültürk, İ., Yılmaz, M., Özmen, A., Tacar, S. Y., Erdal, G. Ş., & Tural, D. G. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211007202 · Cited by 19
“were reported due to high creatinine.(5,7,8) Despite these studies, the FDA reported that 20% of patients with ribociclib plus letrozole combination therapy may have any stage elevation of creatinine.”
BackgroundCyclin-Dependent Kinase Inhibitor–Associated Thromboembolism
Olson, S. R., DeLoughery, T. G., & Shatzel, J. J. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5529 · Cited by 19
Salvia lachnostachys Benth has antitumor and chemopreventive effects against solid Ehrlich carcinoma
Corso, C. R., Stipp, M. C., Adami, E. R., da Silva, L. M., Mariott, M., de Andrade, S. F., Ramos, E. A. D. S., Klassen, G., Beltrame, O. C., Queiroz-Telles, J. E., et al. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04931-3 · Cited by 18
Kettner, N. M., Bui, T. N., Navarro-Yepes, J., Ghotbaldini, S., Quintela, B., Luo, C. K., Lam, N., Rao, X., Raghavendra, A. S., Wang, Y., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01041-1 · Cited by 21
“Human IL-6 was undetectable in plasma from PR-1 – 4.”
Rugo, H. S., Layman, R. M., Lynce, F. C., Liu, X., Li, B. C., McRoy, L., Cohen, A. B., Estévez, M., Curigliano, G., & Brufsky, A. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105570 · Cited by 17
Kwapisz, D. M. (2018) · Breast Cancer · doi:10.1007/s12282-018-0864-6 · Cited by 17
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
Ham, A., Kim, M. H., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Cho, Y. U., Park, B., Kim, S. I., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05750-y · Cited by 17
Beusterien, K. M., Maculaitis, M. C., Hallissey, B., Gaschler, M. M., Smith, M. L., & Law, E. H. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s298670 · Cited by 17
Topçu, A., Yasin, A. İ., Shbair, A. T., Beşiroğlu, M., Şimşek, M., Sucuoglu, Z., Yurtsever, İ., Güçin, Z., Şeker, M., & Türk, H. M. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211027931 · Cited by 17
“Cyclin-dependent kinase 4–6 inhibitors (CDK) are new agents used in the treatment of locally advanced or metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer.(2,3) Ribociclib, a CDK 4/6 inhibitor, is now frequently used in clinical practice for this purpose.”
BackgroundCampone, M., Laurentiis, M. D., Zamagni, C., Kudryavcev, I., Agterof, M. J., Brown-Glaberman, U. A., Palácová, M., Chatterjee, S., Menon-Singh, L., Wu, J., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06543-1 · Cited by 17
Self-citationTorres-Guzmán, R., Ganado, M. P., Mur, C., Marugán, C., Baquero, C., Yang, Y., Zeng, Y. A., Bian, H., Du, J., de Dios, A., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28249 · Cited by 17
“To date, the US Food and Drug Administration (FDA) has approved three CDK4 & 6 inhibitors (CDK4 & 6i) for treatment of hormone receptor-positive (HR+) metastatic breast cancer (MBC); palbociclib [PD0332991; Ibrance; [6]], ribociclib [LEE011; KISQALI; [7]] and abemaciclib [LY2835219; Verzenio; 8, 9].”
BackgroundVisani, L., Livi, L., Ratoša, I., Oražem, M., Ribnikar, D., Saieva, C., Becherini, C., Salvestrini, V., Scoccimarro, E., Valzano, M., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.10.023 · Cited by 17
Watson, N. W., Shatzel, J. J., & Al-Samkari, H. T. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.001 · Cited by 21
Schettini, F., Martínez‐Sáez, O., Falato, C., Santo, I. D., Conte, B., García-Fructuoso, I., Gómez-Bravo, R., Seguí, E., Chic, N., Brasó‐Maristany, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101214 · Cited by 21
“MONALEESA 2/3/7, BOLERO2, EGF30008, DBCG and SOLTI-PATRICIA).(25-35) For these reasons, we conducted a systematic literature review and meta-analysis to assess the clinical validity of IS in HoRþ MBC, regardless of HER2 clinical status.”
MethodApostolidou, K., Zografos, E., Papatheodoridi, A. M., Fiste, O., Dimopoulos, M. A., & Zagouri, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103729 · Cited by 19
“Ribociclib was approved in March 2017 as first-line treatment in combination with letrozole for postmenopausal women with HR + / HER2 (cid:0) advanced breast cancer, based on the results of the phase III study MONALEESA-2 [38].”
BackgroundCyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Guo, Z., Dong, R. W., Wu, Y., Dong, S., & Alahari, S. K. (2025) · Oncogene · doi:10.1038/s41388-025-03378-0 · Cited by 18
“Ribociclib received FDA approval in 2017, with a recommended dosage of 600 mg once daily in a “ 3 weeks on/ 1 week off ” schedule in combination with an aromatase inhibitor or fulvestrant [50, 51].”
Ban, M., Miše, B. P., Majić, A., Dražić, I., & Vrdoljak, E. (2017) · Future Oncology · doi:10.2217/fon-2017-0491 · Cited by 17
Ortega, V., Antón, A., Garau, I., Afonso, N., Calvo, L., Fernández, Y., Martinez‐García, M., Blanco, E., Zamora, P. M., García, M., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.012 · Cited by 17
Guo, Q., Lin, X., Ye, L., Xu, R., Dai, Y., Zhang, Y., & Chen, Q. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00633-9 · Cited by 17
Farhat, F. S., Tarabaih, M., Kanj, A., Aoun, M., Kattan, J. G., Assi, T., & Awada, A. H. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000845 · Cited by 19
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Yang, J., Han, J., Tian, M., Tian, K., Liao, W., & Yan, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s284556 · Cited by 17
Le, V. P., Zhong, L., Narsipur, N., Hays, E. A., Tran, D. K., Rosario, K., & Wilson, L. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.3.327 · Cited by 18
Wang, J., Zhang, Q., Li, Q., Mu, Y., Jing, J., Li, W., Li, W., Wang, J., Yu, G., Wang, X., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00823-4 · Cited by 17
Mouabbi, J. A., Osborne, C. K., Schiff, R., & Rimawi, M. F. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06383-5 · Cited by 19
“The PARSIFAL trial showed that palbociclib with letrozole yielded similar outcomes to those of palbociclib with mPFS median progression-free survival duration, HR hazard ratio, mOS median overall survival duration, AI aromatase inhibitor, 1L first-line, 2L second-line MONALEESA-2 [31] Ribociclib or placebo + letrozole…”
BackgroundInfluentialSun, J. X., Zhong, X., Ma, J., Sun, W., Han, H. S., Soliman, H. H., Loftus, L., Costa, R. L. B., Armaghani, A. J., Soyano‐Muller, A. E., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4295 · Cited by 17
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Tarantino, P., Burstein, H. J., Lin, N., Krop, I. E., Winer, E. P., Schnitt, S. J., Hamilton, E. P., Hurvitz, S. A., Rugo, H. S., Curigliano, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.004 · Cited by 17
Self-citationPhase I trial of ribociclib with platinum chemotherapy in ovarian cancer
Coffman, L. G., Orellana, T. J., Liu, T., Frisbie, L. G., Normolle, D., Griffith, K., Uppal, S., McLean, K., Berger, J., Boisen, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160573 · Cited by 17
“The FDA approved the CDK4/6 inhibitors ribociclib and palbociclib in combination with an aromatase inhibitor for first-line therapy in hormone receptor–positive, HER2-negative breast cancer (19, 21, 22).”
Dalal, A. A., Gagnon‐Sanschagrin, P., Burne, R. M., Guérin, A., Gauthier, G., Small, T., & Niravath, P. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0701-5 · Cited by 18
Suri, G., Chandiwana, D., Lee, A., & Mistry, R. A. (2019) · Journal of health economics and outcomes research · doi:10.36469/9725 · Cited by 17
Rashad, N., Abdelhamid, T., Shouman, S. A., Nassar, H. R., Omran, M. M., Desouky, E. D. E., & Khaled, H. M. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.12.012 · Cited by 17
Metadata
- Authors
- Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan, A., Jakobsen, E., Nusch, A., Burdaeva, O., Grischke, E.-M., Alba, E., Wist, E., Marschner, N., Favret, A. M., Yardley, D., Bachelot, T., Tseng, L.-M., Blau, S., Xuan, F., Souami, F., Miller, M., Germa, C., Hirawat, S., & O’Shaughnessy, J.
- Affiliations
- From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology–Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) — all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) — both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt–Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) — all in Nashville; National Cancer Center...
- The University of Texas MD Anderson Cancer Center (US)
- Université Paris-Sud (FR)
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Stemmer, Salomon M.
- Burris, Howard A.
- Yap, Yoon-Sim
- Sonke, Gabe S.
- Campone, Mario
- Blackwell, Kimberly L.
- André, Fabrice
- Winer, Eric P.
- Janni, Wolfgang
- Verma, Sunil
- Conte, Pierfranco
- Arteaga, Carlos L.
- Cameron, David A.
- Chan, Arlene
- Jakobsen, Erik
- Grischke, Eva-Maria
- Alba, Emilio
- Wist, Erik
- Marschner, Norbert
- Favret, Anne M.
- Yardley, Denise
- Bachelot, Thomas
- Tseng, Ling-Ming
- Blau, Sibel
- Xuan, Fengjuan
- Miller, Michelle
- Germa, Caroline
- O’Shaughnessy, Joyce
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-03
- Volume
- 375
- Issue
- 18
- Pages
- 1738-1748
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528767298
- Cited by
- 2,039
- References
- 24
- Citations by year
- 2026: 167 · 2025: 218 · 2024: 203 · 2023: 214 · 2022: 187 · 2021: 247 · 2020: 206 · 2019: 173 · 2018: 237 · 2017: 166 · 2016: 17
- FWCI
- 176.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Spectrum Pharmaceuticals
- Celgene
- Exelixis
- Celldex Therapeutics
- TG Therapeutics
- Astex Pharmaceuticals
- Agios Pharmaceuticals
- Jounce Therapeutics
- Mersana Therapeutics
- Incyte
- G1 Therapeutics
- Eisai
- Astellas Pharma
- Ipsen
- Genentech
- Chugai Pharmaceutical
- Novartis Institutes for BioMedical Research
- Loxo Oncology
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, hormone receptor-positive HER2-negative breast cancer, advanced breast cancer, first-line therapy, letrozole, endocrine therapy resistance, progression-free survival, myelosuppression, neutropenia, leukopenia
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Staging, Nitriles, Purines, Receptors, Estrogen, Receptors, Progesterone, Triazoles, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
